Pachyman has shown promise in preventing the progression of NASH by maintaining intestinal microflora homeostasis and downregulating the NF-κB/CCL3/CCR1 axis [251]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.